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Abstract
Background: Perturbing Hsp90 chaperone function targets hypoxia inducible factor (HIF) function in a von Hippel-
Lindau (VHL) independent manner, and represents an approach to combat the contribution of HIF to cell renal
carcinoma (CCRCC) progression. However, clinical trials with the prototypic Hsp90 inhibitor 17-AAG have been
unsuccessful in halting the progression of advanced CCRCC.
Methods: Here we evaluated a novel next generation small molecule Hsp90 inhibitor, EC154, against HIF isoforms
and HIF-driven molecular and functional endpoints. The effects of EC154 were compared to those of the
prototypic Hsp90 inhibitor 17-AAG and the histone deacetylase (HDAC) inhibitor LBH589.
Results: The findings indicate that EC154 is a potent inhibitor of HIF, effective at doses 10-fold lower than 17-AAG.
While EC154, 17-AAG and the histone deacetylase (HDAC) inhibitor LBH589 impaired HIF transcriptional activity,
CCRCC cell motility, and angiogenesis; these effects did not correlate with their ability to diminish HIF protein
expression. Further, our results illustrate the complexity of HIF targeting, in that although these agents suppressed
HIF transcripts with differential dynamics, these effects were not predictive of drug efficacy in other relevant assays.
Conclusions: We provide evidence for EC154 targeting of HIF in CCRCC and for LBH589 acting as a suppressor of
both HIF-1 and HIF-2 activity. We also demonstrate that 17-AAG and EC154, but not LBH589, can restore
endothelial barrier function, highlighting a potentially new clinical application for Hsp90 inhibitors. Finally, given
the discordance between HIF activity and protein expression, we conclude that HIF expression is not a reliable
surrogate for HIF activity. Taken together, our findings emphasize the need to incorporate an integrated approach
in evaluating Hsp90 inhibitors within the context of HIF suppression.
Background
Hypoxia inducible factor (HIF) is a master regulator of
t h eh y p o x i cr e s p o n s ea n dp l a y sac r i t i c a lr o l ei nt h e
development and progression of numerous solid cancers
[1,2]. HIF functions as a heterodimeric transcription fac-
tor composed of an oxygen regulated a-subunit and a
constitutively expressed b-subunit (or ARNT). HIF
activity is tightly regulated by oxygen tension wherein
its activity is restrained under oxygenated conditions via
von-Hippel Lindau (VHL) ubiquitin ligase mediated
degradation of the a subunit [3]. In contrast, tumor
hypoxia facilitates HIF-a stabilization, dimerization, and
transcriptional activation. HIF regulates a multitude of
genes that contribute to pro-tumorigenic processes
including invasion, angiogenesis and therapeutic resis-
tance [2,4-6]. Importantly, inhibition of HIF function
suppresses tumor formation and progression, and
restores treatment sensitivity, highlighting HIF as a clini-
cally relevant therapeutic target [1,7].
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highly vascularized and among the most lethal kidney
tumors [8]. CCRCC, with its defined loss of VHL func-
tion and resulting constitutive HIF expression and activ-
ity, is a useful model to decipher the role of HIF in
cancer progression and to evaluate HIF targeting strate-
gies. Although the sufficiency of HIF for CCRCC
remains somewhat controversial [9], HIF is a major par-
ticipant in CCRCC within the context of VHL loss
[10-13]. Of the two main pro-tumorigenic HIF-a iso-
forms, HIF-2a elicits tumor formation in CCRCC xeno-
graft models [10,14] and appears to be more commonly
upregulated in CCRCC relative to HIF-1a [4]. However,
HIF-1a driven CCRCC xenograft models have also been
documented [15], as well as compensatory mechanisms
between the two isoforms [16]. Therefore, the targeting
of both HIF isoforms may represent the most effective
therapeutic approach. In spite of this, few studies have
addressed the ability of candidate agents to target both
isoforms.
A number of generalized HIF targeted approaches
have been employed, including modulation of HIF
expression, transcription, translation, dimerization,
transactivation, and stability [17-23]. Small molecule
inhibitors of the chaperone heat shock protein 90
(Hsp90) represent a growing class of clinically utilized
anti-tumorigenic agents that have been collectively
exploited as an alternative means of targeting HIF-a,
given their shared ability to disrupt the ATP dependent
chaperone activity of Hsp90 and block the protein fold-
ing of respective Hsp90 clients. HIF is an Hsp90 client
protein [24] and we, and others, have shown that per-
turbing Hsp90 function with geldanamycin (GA) and
small molecule derivatives promotes HIF-1a and HIF-
2a protein degradation and suppression of transcrip-
tional activity [25-27]. Importantly, Hsp90 targeted
approaches bypass the requirement for both VHL and
oxygen, instead utilizing the ubiquitin ligase RACK1
[25,28]. Therefore, these agents hold promise in tumor
environments where VHL function is compromised, as
in CCRCC or tumor hypoxia. In support of this premise,
the Hsp90 inhibitors GA, 17-(allylamino)-17-demethoxy-
geldanamycin (17-AAG or Tanespimycin) and 17-
dimethylaminoethylamino-17-demethoxygeldanamycin
(17-DMAG or Alvespimycin) demonstrate anti-tumori-
genic and anti-angiogenic properties in both in vitro and
in vivo animal models, due in part to their ability to
inhibit HIF function [29-33]. However, despite the pro-
mising pre-clinical actions of these inhibitors, clinical
trials with 17-DMAG have been relatively unsuccessful
for CCRCC and other solid tumors [34-36]. These fail-
ures highlight the critical need to further evaluate the
effects of Hsp90 targeting agents upon HIF dependent
signaling and angiogenesis in CCRCC and other cancers.
Since the advent of 17-AAG, numerous Hsp90 inhibi-
tors exhibiting enhanced potency and diminished toxi-
city have been developed [37-41], leaving open the
possibility that these next generation agents may
demonstrate increased potency and efficacy in vivo.I n
addition to these direct Hsp90 inhibitors, histone deace-
tylase (HDAC) inhibitors, such as the clinically utilized
LBH589 (Panobinostat), indirectly inhibit Hsp90
through protein hyperacetylation, leading to loss of cha-
perone function [42-44] and comparable inhibition of a
subset of Hsp90 client proteins [45-47]. Similar to
Hsp90 inhibitors, HDAC inhibitors ablate HIF levels
and activity in several models [42,45,48-50]. Although
one report examined the effects of HDAC inhibition
upon HIF-1 expression in CCRCC cells [50] and another
utilized LBH589 in combination with rapamycin [15], an
analysis of these agents upon HIF-2 expression or activ-
ity is lacking, an important oversight given that a major-
ity of CCRCC tumors preferentially express HIF-2 [4].
Moreover, no reports have directly compared the effects
of ATP based competitive Hsp90 inhibitors with HDAC
inhibitors such as LBH589 with respect to their respec-
tive ability to suppress the activity of HIF isoforms.
In this study, we utilized a prototypic next generation
Hsp90 inhibitor, EC154, representing a novel synthetic
compound with enhanced potency and diminished toxi-
city relative to 17-AAG. EC154 is a compound with
improved properties (potency, pharmacokinetic and
pharmacodynamic) over BIIB021, the first oral synthetic
Hsp90 inhibitor to reach clinical trials [51]. EC154 binds
to the Hsp90 ATP binding site in a manner similar to
EC144 [52]. Towards the goal of identifying more potent
HIF targeting agents, we evaluated the ability of 17-
AAG, EC154, and LBH589 to suppress HIF activity and
angiogenic potential in CCRCC cells. We show herein
that although these agents exert inhibitory effects
against HIF activity, they exhibited differential time and
dose dependent responses not consistently linked to
relative HIF protein expression. Our results therefore
provide valuable guidance on the use of these agents as
HIF inhibitors and highlight the biological complexity of
Hsp90 inhibition upon suppression of HIF activity and
downstream targets. Further, our results suggest that the
evaluation of HIF expression in tissues as a surrogate for
therapeutic efficacy may not suffice as a reliable indica-
tor of HIF suppression.
Methods
Reagents and antibodies
The Hsp90 inhibitors 17-(Allylamino)-17-demethoxygel-
danamycin (17-AAG) and EC154 were provided by the
NCI Developmental Therapeutics Program and Biogen
IDEC, respectively. The HDAC inhibitor LBH589 was
provided by Dr. Peter Atajda (Novartis). HIF-1a (100-
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Biologicals. Additional antibodies included GAPDH
(9295) from Sigma; RACKI (17754) and topoisomerase
II (13059) from Santa Cruz; P-ERKT202/Y204 (4370), ERK
(4695), P-srcY416 (2101), src (2108) from Cell Signaling;
and P-FAKY397 (44-624G) and FAK (AHO-0502) from
Invitrogen.
Cell culture
UMRC2 and 786-O cells were provided by Dr. M.I. Ler-
man and Dr. R. Klausner (NCI, National Institutes of
Health). UMRC2-VHL replaced cells were made as pre-
viously described [25] and 786-O VHL-replaced cells
were provided by Dr. W.G. Kaelin (Dana-Farber Cancer
Institute). All CCRCC cell lines were maintained in buf-
fered Dulbecco’s modified Eagle’s medium (Thermo
Scientific) supplemented with 10% fetal bovine serum
(Gibco), L-glutamine (Thermo Scientific), and penicillin/
streptomycin (Mediatech). Human umbilical vascular
endothelial cells (HUVEC) were purchased from Invitro-
gen and maintained in Medium 200/LSGS (Gibco). All
cells were maintained at 37°C and 5% CO2
Western blots
Nuclear preparations were prepared as previously
described [25]. Briefly, cells were washed in phosphate-
buffered saline, collected using a hypotonic buffer (20
mM HEPES, 5 mM MgCl2, 5 mM NaCl, 1 mM EDTA,
pH 7.9) containing protease inhibitors (Roche), nuclear
pellets were collected following addition 10% Nonidet P-
4, lysed in hypertonic buffer (20 mM HEPES, 400 mM
NaCl, 1 mM EDTA) containing protease inhibitors, and
supernatant collected. For whole cell lysates, cells were
washed with phosphate-buffered saline, incubated in
lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1%
NP40, 1 mM EDTA) containing protease inhibitors, and
supernatant collected. All protein concentrations were
determined by BCA method (Thermo Scientific).
qRT-PCR analysis
CCRCC cells were treated with 17-AAG, EC154,
LBH589 or DMSO solvent control. Total RNA was
extracted with the RNeasy Kit (Qiagen, Valencia, CA).
Total RNA (1 μg) was used for reverse transcription
with SuperScript
® III First-Strand Synthesis SuperMix
for qRT-PCR (Invitrogen,) and resulting cDNA was
used as a template for quantitative Real-time PCR analy-
sis. The ratio of GLUT1, VEGF, LOX1 and OCT-4 to a-
tubulin was measured with real-time-quantitative PCR
(iQ5 Multicolor Real-Time PCR Detection System, Bio-
Rad Laboratories, Hercules, CA) using iQ5 optical sys-
tem software. The reaction mixture contained 12.5 μl
SYBR green mix (Bio-Rad), 2 μl of mixed primers, and 2
μl cDNA template. The final volume was adjusted with
H2Ot o2 5μl. Annealing temperature was 55°C for all
reactions. Fluorescent products were measured by a sin-
gle acquisition mode after each cycle. Primers are as fol-
lows: a-tubulin: F-AACGTCAAGACGGCCGTGT, R-
GACAGAGGCAAACTGAGCAC; GLUT1: F-GTGGGC
ATGTGCTTCCAGTA, R-ACAGAACCAGGAGCA-
CAGTGAA; VEGF: F-AGGCCAGCACATAGGAGAGA,
R-TTTCCCTTTCCTCGAACTGA; CAIX: F-GGGTGT
CATCTGGACTGTGTT, R-CTTCTGTGCTGCCTTC
TCATC; qLOXI: F-ATGAGTTTAGCCACTTGTACC
TGCTT, R-AAACTTGCTTTGTGGCCTTCA; OCT-4:
F-GACAACAATGAGAACCTTCAG GAGA, R-CTGGC
GCCGGTTACAGAACCA.
Lentiviral infection and luciferase reporter assays
The Cignal Lenti-HIF Reporter system (SABiosciences)
was used to stably transduce CCRCC cells with consti-
tutively expressed renilla luciferase and HIF-regulated
firefly luciferase constructs. UMRC2 and 786-0 cells
were grown to 60-70% confluence and infected for 24 h
according to the manufacturer’s specifications. Cells
were placed under puromycin selection and positive
clones were expanded. For analysis of HIF activity, cells
at 70% confluency were treated for 16 h with or without
inhibitors, lysed, and dual luciferase activity analyzed
(Promega). Experiments were performed in triplicate
and arbitrary values normalized to renilla luciferase
levels.
Immunoassays
UMRC2 and 786-O cells were pre-treated for 4 h with
the indicated compounds in low serum (3% FBS)
medium. Cells were rinsed with PBS and then incu-
bated with freshly prepared treatments in similar
m e d i u mf o r1 6hu n d e ro rn o r m o x i ao rh y p o x i a( 1 %
O2). Conditioned medium was collected following
brief centrifugation and whole cell lysate was col-
lected as described. VEGF and uPA concentrations
were measured by ELISA (R&D Systems) according to
the manufacturer’s instructions, and normalized to
total protein concentration of the conditioned
medium.
Tubule formation assay
HUVEC cells were serum starved overnight (0.1%
M200) and plated (15,000 cells/well) in 96-well plates
pre-coated with 50 μL of phenol-red free growth factor
reduced Matrigel (BD Biosciences) with the indicated
treatments. CCRCC conditioned medium was collected
and added to HUVEC cells for 6 h. Effects on angiogen-
esis were determined by quantifying branch points in 6
replicate wells (1 field per well; 40X) for each treatment
and are presented as percent of untreated control with
standard deviation.
Bohonowych et al. BMC Cancer 2011, 11:520
http://www.biomedcentral.com/1471-2407/11/520
Page 3 of 17Cell migration
Cell migration was assessed using Boyden chambers (0.8
μm; BD Biosciences). Cells were plated into the upper
chamber in reduced serum DMEM (0.1%) with complete
DMEM in the lower chamber and indicated agents
added to both chambers. At 24 h, inserts were washed
with PBS, the non-motile cells removed with cotton
swabs, and the migratory cells fixed in formaldehyde,
visualized with 0.1% crystal violet, and counted. The
data presented represent the mean value from 4 repli-
cates per treatment.
Cell viability
CCRCC cells (5,000) were plated in 96-well plates,
treated with 17-AAG, EC154, LBH589 or vehicle for
16 h and assessed for cell viability using the Cell-Titer
Blue Reagent as per the manufacturer’s instructions
(Promega).
Electrical Cell Substrate Impedance Sensing Assay (ECIS)
Changes in endothelial cell monolayer permeability
were determined using the well established method of
measuring electrical impendence [53]. HUVECs were
seeded onto ECIS 8W10E+electrode arrays (Applied
Biophysics, Troy, NY) precoated with human plasma
fibronectin (Invitrogen) at 100 μg/mL in 0.15 M NaCl,
0.01 M Tris, pH 8.0. Transendothelial electrical resis-
tance (TEER), an index of endothelial cell barrier func-
tion, was measured using an ECIS Model 1600
instrument (Applied Biophysics, Troy, NY). Cells were
allowed to form a confluent monolayer and cell barrier
until a plateau was reached (~3 days). In order to eval-
uate the ability of 17-AAG to reverse the effects of
agents known to disrupt barrier function, culture med-
ium was replaced with fresh EGM-2 containing the
barrier disruptor, VEGF (50 ng/mL) in the absence or
presence of 17-AAG (1 μM), and impedance was mea-
sured every 5 min at 15 kHz frequency. In order to
evaluate the effects of CCRCC conditioned medium
(CM) on endothelial cell barrier function, culture med-
ium was replaced with CM collected for 24 h from 1 ×
10
6 UMRC2 or 786-0 cells in the absence or presence
of 17-AAG (1 μM), EC154 (100 nM), or LBH589 (100
nM). HUVEC-CM was used as a control for possible
nutrient depletion. The traces shown represent the
mean of duplicate wells for each treatment.
Statistical analysis
Statistical significance was determined using one-way
ANOVA followed by one-tailed student’sT - t e s t s .I C 5 0
values were calculated using SigmaPlot10 (Systat)
wherein curves were fitted to either a 3-parameter logis-
tical or 4-parameter sigmoidal plot (R
2 = 0.695-0.996).
Results
Differential effects of inhibitors upon HIF protein
expression are isoform and cell context dependent
Given the prominent tumorigenic role of HIF in the
majority of solid tumors, it is critically important to
include evaluation of this metric when evaluating the
efficacy of novel next generation Hsp90 inhibitors. To
begin to address this question, we performed a compre-
hensive evaluation of the effects of 17-AAG, EC154, and
LBH589 upon cellular HIF-1a and HIF-2a protein
expression and activity in UMRC2 cells which express
both HIF-1a and HIF-2a proteins and 786-O cells,
which express only the HIF-2a isoform [54,55]. All
three agents reduced HIF-1a expression in UMRC2,
with EC154 more effective than 17-AAG, and LBH589
almost completely eliminating HIF-1a expression (Fig-
ure 1). Interestingly, the HIF-2a expression in 786-O
cells was refractory to these treatments. Equally unex-
pectedly, LBH589 elicited a reproducible increase in
HIF-2a expression in both 786-O and UMRC2 cells. In
contrast to the effects in 786-O, 17-AAG and EC154
reduced HIF-2a expression in UMRC2, indicating that
the effects of these drugs upon HIF isoforms may be
cell context dependent. It has been shown that the VHL
independent Hsp90 mediated destruction pathway for
HIF-1a utilizes the adaptor protein RACK1 [28]. Given
the apparent insensitivity of HIF-2a protein in response
to Hsp90 inhibition, we examined the relative levels of
RACK1 in these cell lines. As shown in Figure 1,
RACK1 expression was abundant in both cell lines and
was unaffected by drug treatment, indicating that suffi-
cient RACK1 was available to mediate HIF-a degrada-
tion. Therefore, the mechanism for the sustained HIF-
2a protein stability in 786-O cells following Hsp90 inhi-
bition remains to be further clarified.
Comparative effects of inhibitors upon HIF transcriptional
activity
To correlate HIF protein expression with HIF activity fol-
lowing drug exposure, we next evaluated HIF target gene
levels by qRT-PCR. Dose curves at 16 h treatments were
used to determine the most efficacious concentration for
each drug (Additional file 1: Figure S1), and these optimal
concentrations were utilized for all further studies (1 μM
17-AAG, 100 nM EC154, and 100 nM LBH589). VHL
replaced derivatives were included as a relative negative
control for HIF activity. The co-expression of both HIF-a
isoforms in UMRC2 cells [55], coupled with the potential
ability of the suppression of one HIF isoform to modulate
expression and activity of the remaining protein [56-58],
present challenges in evaluating the effects of these inhibi-
tors upon HIF-1 and HIF-2 function. To address this
question, we selected five transcripts, two of which are
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Page 4 of 17Figure 1 HIF-1a and HIF-2a expression is differentially modulated by Hsp90 inhibition in CCRCC cells. UMRC2 and 786-O cells were
treated for 20 h with the Hsp90 inhibitors 17-AAG (1 μM), EC154 (100 nM), the HDAC inhibitor LBH589 (100 nM), or DMSO vehicle control.
Nuclear protein was analyzed for HIF-1a and HIF-2a and cytosolic protein was analyzed for RACK1 by SDS-PAGE and Western blot.
Topoisomerase II and GAPDH were used as nuclear and cytosolic loading controls, respectively. Bands corresponding to HIF-1a and HIF-2a
Western blots were quantified, normalized to TOPOII, and are expressed as a percentage of control samples.
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Page 5 of 17preferentially regulated by HIF-1a (CAIX, LOX1), two by
HIF-2a (GLUT1, OCT-4), and one influenced by both iso-
forms (VEGF). As shown in Figure 2, all three drugs signif-
icantly inhibited mRNA expression of the selected
transcripts in UMRC2, with LBH589 exhibiting the most
profound suppression, comparable to VHL replaced cells.
This result also indicates that the LBH-589 mediated
increase in HIF-2a expression did not elicit a comparable
increase in HIF-2a activity. Although CAIX and VEGF
appeared to be more resistant to suppression in EC154
treated cells, this trend was not observed in subsequent
experiments (Figure 3). The effect of these agents in 786-
O was generally more modest when compared to UMRC2,
although the general trends were mirrored, with 17-AAG
demonstrating enhanced suppression of HIF driven tran-
scripts when compared with EC154 (Additional file 1: Fig-
ure S1). Although CAIX and LOX-1 are reported to be
controlled by HIF-1 activity [59,60], the apparent suppres-
sion of these transcripts following drug treatments in 786-
O indicates that HIF-2a may also influence their tran-
scriptional regulation.
The clinical administration of therapeutic agents results
in a dynamic response largely influenced by concentra-
tion flux and gradients within the tumor. Our data in
Figure 2 indicate that HIF targets exhibit differential
sensitivity to these agents, a finding that may profoundly
influence in vivo drug efficacy and contribute to
dynamic responses. To more carefully analyze this para-
meter, we examined the time-dependent effects of these
agents over a period of 2-16 h. As shown in Figure 3, all
three inhibitors elicited a time dependent suppression of
HIF regulated transcripts, as well as variable kinetics.
CAIX transcript levels were more refractory to suppres-
sion by 17-AAG in both cell lines at earlier time points,
while the remaining HIF transcripts in UMRC2 cells
demonstrated a rapid and maximal suppression by 2 h.
In 786-O cells, VEGF message was refractory to inhibi-
tion at earlier time points. With EC154 treatment, CAIX
exhibited earlier suppression, while VEGF message was
refractory at earlier time points in both cell lines.
Although EC154 mediated suppression of transcripts
occurred with slower kinetics, the overall extent of sup-
pression at later time points was comparable to that
observed with 17-AAG. Interestingly, LBH589 demon-
strated the most potent suppression of transcripts in
UMRC2, while 786-O transcripts were more refractory
by comparison. Part of the complexity observed with
HIF driven transcripts may be due to additional signal-
ing pathways and effectors that contribute to their regu-
lation [61-63] as supported by the differential expression
of these transcripts in VHL replaced 786-O cells (Addi-
tional file 1: Figure S1).
Comparative effects of inhibitors upon VEGF promoter
activity and VEGF secretion
To uncouple some of this complexity and to evaluate
the specific effects of these agents upon HIF-dependent
transcription, we utilized a HIF-driven luciferase repor-
ter assay system in UMRC2 and 786-O cells. Consistent
with our qRT-PCR results, both 17-AAG and EC154
Figure 2 The inhibitors 17-AAG, EC154, and LBH589 inhibit HIF-dependent gene transcription in CCRCC cells. The CCRCC cell line
UMRC2 was treated for 16 h with inhibitors as in Figure 1. Total mRNA was isolated and HIF-a regulated genes analyzed by qRT-PCR. Values
were normalized to GAPDH and are presented relative to control cells, with standard deviation shown. All drug treatments significantly reduced
all transcript levels (*) as determined by ANOVA and Student’s t-test (p < 0.05).
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in both cell types, with a greater extent of inhibition
observed in UMRC2 (Figure 4a). However, within this
model, LBH589 demonstrated comparable effects upon
HIF dependent reporter expression in both cell lines,
despite eliciting comparatively greater suppression in
UMRC2 as determined by qRT-PCR (Figures 2 and 3).
Given the variations between HIF-a protein expression
and HIF transcriptional activity, we next examined
whether the expression of HIF-regulated proteins mir-
rored the trends of their transcript levels. The HIF sig-
naling pathway regulates numerous pro-tumorigenic
Figure 3 Time dependent evaluation of 17-AAG, EC154, and LBH589 upon HIF-dependent gene transcription. The CCRCC cell lines
UMRC2 and 786-O were treated as in Figure 2 for the indicated times, total mRNA isolated and HIF-a regulated genes analyzed by qRT-PCR.
Values were normalized to GAPDH and are presented relative to values at time zero with standard deviation shown.
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Page 7 of 17Figure 4 17-AAG, EC154, and LBH589 suppress HIF-dependent reporter gene expression and VEGF secretion.( a) CCRCC cells were
transiently transfected with either a constitutive or VEGF HRE-driven luciferase reporter construct, treated for 16 h with inhibitors, and luciferase
enzyme activity determined in whole cell lysates. All drug treatments significantly reduced HIF-dependent reporter gene expression (*) in both
cell types with the exception of EC154 in 786-O, as determined by ANOVA and Student’s t-test (p < 0.05). (b) CCRCC cells were pre-treated for 4
h with inhibitors in reduced serum DMEM (3% FBS), and incubated for an additional 16 h with freshly prepared treatments in reduced serum
medium. Conditioned medium was collected and VEGF levels were analyzed by ELISA. Values were normalized to total protein in conditioned
medium and presented relative to controls, with standard deviation. All drug treatments significantly reduced VEGF secretion (*) in both cell
types, as determined by ANOVA and Student’s t-test (p < 0.05).
Bohonowych et al. BMC Cancer 2011, 11:520
http://www.biomedcentral.com/1471-2407/11/520
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[2,64,65] and VEGF is a major contributor of HIF-driven
angiogenesis. Hsp90 inhibitors such as 17-AAG decrease
HIF-dependent production of CCRCC derived VEGF
[66] and LBH589 has been shown to inhibit VEGF sig-
naling in endothelial cells [67]. To further interrogate
drug mediated effects upon HIF, we next evaluated the
effects of these agents upon VEGF secretion. As shown
in Figure 4b, all three drugs significantly reduced
secreted VEGF levels in both cell types, congruous with
the qRT-PCR results (Figure 3). Interestingly, 17-AAG
and EC154 appeared somewhat less effective in reducing
intracellular VEGF levels (Additional file 2: Figure S2).
The significance of this is not entirely clear given that
the secreted protein represents the biologically relevant
fraction initiating HIF-mediated angiogenesis. However,
this finding illustrates another level of complexity in
that intracellular and secreted pools of HIF target pro-
teins may be differentially susceptible to therapeutics.
Dose dependent efficacy of inhibitors upon VEGF and
uPA secretion
In addition to VEGF, HIF activation promotes secretion of
the pro-angiogenic urokinase plasminogen activator (uPA)
[68,69]. In conjunction with its receptor uPAR, uPA regu-
lates the plasminogen pathway to stimulate MMP activity
and influence bioavailability of many HIF-regulated
growth factors [70]. To examine the relative potency of
these agents, we evaluated the dose dependent effects of
these agents upon secreted VEGF and uPA in UMRC2
cells. Surprisingly, by this metric, EC154 and LBH589
were significantly more potent than 17-AAG (Figure 5),
evidenced by their far more robust suppression of both
VEGF and uPA (IC50 = 0.006-0.28 μM) as compared 17-
AAG (14.8-31.6 μM). Interestingly, LBH589 demonstrated
the strongest potency against uPA relative to the other
agents (IC50 =0 . 0 0 6μM). Cell viability analysis by MTT
assay supports that these drug dependent effects were due
specifically to modulation of protein secretion and not a
result of decreased cell proliferation (Additional file 3: Fig-
ure S3). We previously demonstrated that GA effectively
reduced VEGF transcript expression and associated angio-
genesis in RCC cells under hypoxic conditions [25]. To
confirm that EC154 and LBH589 similarly maintain effi-
cacy under hypoxia, UMCRC2 and 786-O cells were
exposed to hypoxia [25,71] for 16 h in either the presence
or absence of these agents. As shown (Additional file 4:
Figure S4), both EC154 and LBH589 potently suppressed
uPA and VEGF secretion under hypoxia.
Dose dependent effects of inhibitors upon CCRCC cell
motility and associated molecular effectors
The ability of these agents to elicit suppression of VEGF
and uPA secretion at doses several log below their
suggested optimal dose was intriguing. To explore
whether low doses of these agents were able to suppress
additional parameters of tumorigenicity, we evaluated
their effects upon CCRCC cell motility, a property asso-
ciated with HIF activity in CCRCC and other models
[72-74], and additionally influenced by both VEGF and
uPA. As shown in Figure 6a, 17-AAG and EC154 com-
pletely ablated UMRC2 cell motility at doses as low as
0.01 nM. In support of this finding, femtomolar levels of
geldanamycin derivatives have been previously reported
to inhibit invasion in human glioblastoma and myosar-
coma cells through a proposed mechanism distinct from
degradation of Hsp90 client proteins [75]. To further
correlate our migration results with changes in relevant
pro-motility signaling mediators, we examined the con-
centration dependent effects of these agents upon ERK,
FAK, and src [76,77]. As shown in Figure 6b, only the
high drug concentration of each agent suppressed ERK
and FAK activation in UMRC2, the latter only observed
with EC154. Src activation was not altered with either
17-AAG or EC154 and was only modestly reduced by
the higher dose of LBH589. In contrast, ERK, FAK, and
src phosphorylation were more susceptible to drug
treatment in 786-O cells, wherein high concentrations
of all three drugs reduced phosphorylation of these sig-
naling mediators. Interestingly, low dose 17-AAG
appeared to increase src phosphorylation, an effect most
profoundly observed in 786-O cells, (10 pM 17-AAG),
and not as readily observed with EC154. This 17-AAG
mediated upregulation in src phosphorylation correlates
with its reported ability to activate src activity in osteo-
clasts [78]. The drug mediated suppression of cell moti-
lity in UMRC2 independent from equivalent suppression
of either FAK or src activity suggests that these agents
impact upon alternative pro-motility factors. One likely
candidate is uPA, given the ability of low drug concen-
trations to potently impair uPA secretion (Figure 5).
Given that uPA regulates cell motility in part via integ-
rin signaling [79], our findings suggest that these agents
may impair motility in part via blockade of an uPA-
integrin dependent pathway. Other possibilities include
changes to the acetylation status of tubulin following
inhibition of either Hsp90 or HDACs [80,81].
Inhibitors potently suppress CCRCC mediated tubule
formation but differentially modulate endothelial barrier
function
CCRCC tumors are among the most vascular, demon-
strating the clinically important role of HIF in modulat-
ing levels of secretory factors that influence the tumor
microenvironment. Given that low doses of these inhibi-
tors elicited potent effects upon CCRCC motility, signal-
ing, and secretion of uPA and VEGF, we examined the
effects of these agents upon CCRCC mediated
Bohonowych et al. BMC Cancer 2011, 11:520
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Page 9 of 17Figure 5 Ability of agents to suppress VEGF and uPA secretion in UMRC2 cells. UMRC2 cells were pre-treated for 4 h with the indicated
doses of agents in reduced serum as in Figure 4. Conditioned medium was collected and both VEGF and uPA levels were analyzed by ELISA.
Values were normalized to total protein in conditioned medium and are presented as percent of cytokine secretion relative to control with
standard deviation.
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Page 10 of 17Figure 6 17-AAG and EC154 suppress UMRC2 cell motility and differentially modulate ERK, FAK, and src activation.( a) Serum starved
UMRC2 cells were plated in transwell Boyden chambers for 16 h with a serum gradient of 0.1% (top) to 10% (bottom) in the presence of serially
diluted concentrations of the indicated Hsp90 inhibitors. Migrating cells were fixed with 3.7% formaldehyde, stained with Crystal Violet and
counted, with standard deviation shown. All drug treatments significantly inhibited migration in both cell types (*), as determined by ANOVA
and Student’s t-test (p < 0.05). (b) UMRC2 and 786-O cells were treated for 20 h with the indicated doses of inhibitors and phosphorylated and
total ERK, FAK, and src were analyzed by SDS-PAGE and Western blot.
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Page 11 of 17angiogenesis. Although previous reports have demon-
strated the ability of these agents to inhibit tubule for-
mation initiated by a single specific growth factor
[31,67], tumors promote angiogenesis via secretion of a
complex mixture of growth factors. We therefore deter-
mined the relative ability of these agents to inhibit
tubule formation when challenged by exposure to the
physiologically relevant secreted milieu derived from
CCRCC cells. As shown in Figure 7, conditioned med-
ium derived from both UMRC2 and 786-O cells stimu-
lated HUVEC tubule formation within 6 h, an effect
attenuated with the addition of each of the three drugs.
Importantly, low dose treatment of all three drugs
reduced tubule formation to levels comparable to the
untreated control, and high dose treatment of the ATP
Hsp90 inhibitors 17-AAG and EC154 further inhibited
tubule formation to levels below untreated controls.
A complementary critical component of vessel func-
tion is permeability. Paracrine signals from the tumor
promote the weakening of endothelial cell junctions. As
a result of this diminished barrier function, the tumor
vasculature becomes characteristically disordered,
permeable, and leaky. This enhanced permeability pro-
motes the ability of cancer cells to breach the vascula-
ture in a process termed transendothelial migration
(TEM) [82]. VEGF is among the best studied mediators
of endothelial paracellular permeability [83]. Although
CCRCC tumors are highly angiogenic, no reports have
investigated the cumulative effects of CCRCC secreted
factors upon endothelial barrier function, nor have any
of the agents herein been evaluated for their capacity to
counteract paracrine tumor factors that breach endothe-
lial cell integrity. To examine endothelial barrier func-
tion upon challenge with CCRCC conditioned medium,
and the ability of the inhibitors to counteract potential
effects of this exposure, we utilized electric cell-substrate
impedance sensing (ECIS). As shown in Figure 7b, con-
ditioned medium from both UMRC2 and 786-O cells
dramatically reduced endothelial cell barrier function.
This effect was not replicated by conditioned medium
from HUVECs, validating CCRCC derived specific
effects. Moreover, the effect of CCRCC conditioned
medium was greater than that of VEGF alone (Addi-
tional file 5: Figure S5) supporting the notion that
tumor cells modulate endothelial cell integrity via a
complex mixture of effectors. Importantly, both 17-
AAG and EC154 were able to restore barrier function in
HUVECs challenged with CCRCC conditioned medium.
Although 17-AAG has been previously demonstrated to
restore barrier function upon exposure to a single cyto-
kine [84,85], this is the first study to highlight its ability
to maintain endothelial cell integrity upon exposure to a
complex mixture of tumor derived paracrine factors.
Strikingly, a similar recovery effect was not observed
with LBH589. That LBH589 did not restore endothelial
barrier function in a similar manner is unexpected and
suggests the possibility a non-Hsp90 mediated effect.
Discussion
Given the well established role of HIF in CCRCC, and
its seemingly universal involvement in the progression
of diverse solid tumors, it is critically important to eval-
uate the HIF targeting ability of next-generation Hsp90
inhibitors. However, surprisingly few studies have exam-
ined this particular aspect of these agents. The results
from this study indicate that standard endpoints for HIF
function may be less informative than previously indi-
cated, and that the apparent complexity of inhibitor
effects requires a more functionally based and integra-
tive approach. One example of this complexity is
demonstrated by our findings that although all three
compounds significantly reduced HIF-1a protein levels,
consistent with previous reports [25-27,45], 17-AAG
a n dE C 1 5 4d i dn o ta p p r e c iably diminish HIF-2a levels,
and surprisingly, LBH589 increased HIF-2a expression.
To our knowledge, this is the first report to examine the
effect of an HDAC inhibitor on HIF-2a levels, and more
significantly, to demonstrate an HDAC dependent
increase in protein expression. It remains unclear
whether the mechanism of LBH589 mediated increase
of HIF-2a protein may be due to changes in protein
degradation or synthesis. Further, the requirement of
RACK1 for Hsp90-inhibition mediated HIF-2a degrada-
tion has not been established. The differential response
of the HIF isoforms is not without precedent, in that
isoform specificity for HIF-1a and HIF-2a has been
demonstrated during oxygen and VHL independent
destruction pathways [86,87]. However, of greater rele-
vance to this study is that the LBH-589 mediated
increase in HIF-2a expression did not elicit a compar-
able increase in HIF-2a activity.
Our findings reinforce the theme that HIF expression
and activity may be uncoupled events, a notion pre-
viously observed following treatment with proteasomal
inhibitors [59]. First, although LBH589 increased HIF-2
expression, all other parameters of HIF activity support
an overall suppressive effect. Given that HIF activity is
r e g u l a t e db ya c e t y l a t i o n ,i ti sv e r yp o s s i b l et h a tt h e
increase in HIF acetylation by LBH-589 is inhibitory.
Further, increased acetylation has also been shown to
inhibit Hsp90 chaperone activity [44], which may further
suppress HIF-2 activity. Second, all three drugs dimin-
ished HIF-1a and HIF-2a dependent transcription
within 2 h of treatment, prior to decreases in protein
levels [25,88], and data not shown. Although EC154 and
17-AAG demonstrated approximately equivalent kinetics
of suppression, exposure of cells to low concentrations
of EC154 (10-fold lower levels than the experimental
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Page 12 of 17Figure 7 17-AAG, EC154, and LBH589 suppress CCRCC mediated tubule formation and differentially modulate endothelial barrier
function. a) Serum starved (0.1%) HUVEC cells were plated on growth factor reduced Matrigel in the presence of CCRCC conditioned medium
(UMRC2 or 786-0) in the presence or absence of 17-AAG, EC154, or LBH589. Tubule formation was imaged at 6 h from 6 replicate wells of a 96-
well plate (1 field per well at 40 × magnification), branch points counted, and presented as a percent of untreated control with standard
deviation. Conditioned medium from both cell types significantly induced tubule formation (*) as determined by Student’s t-test (p < 0.05). Drug
treatments that significantly reversed the effects of conditioned medium are indicated (**) as determined by ANOVA and Student’s t-test (p <
0.05). b) Monolayers of HUVEC cells were allowed to reach a minimal TEER plateau and subsequently incubated with conditioned medium from
UMCRC2 (left panel) or 786-O cells (right panel) in the presence or absence of 17-AAG, EC154, or LBH589. Conditioned medium from HUVEC
cells was used as a negative control. Impedance was measured at 5 min intervals, normalized to levels just prior to the addition of effectors, and
presented relative to untreated control. The traces shown represent an average of two replicates per condition.
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Page 13 of 17100 nM) did not elicit detectable increases in src phos-
phorylation, indicating an improved profile compared
with 17-AAG.
Our data highlight the complexity of drug targeting, in
that the drug mediated suppression of HIF target genes
varied dynamically with time and dose, and differential
sensitivity was observed in a transcript and cell context
dependent manner. This complexity is not surprising
given that additional modifiers may contribute to the
net effects of Hsp90 inhibition. For example, NF-kB pro-
motes HIF-1a transactivation in an acetylation sensitive
manner [89] and coordinates suppressive effects upon
NF-kB, and Hsp90 may contribute to the robust inhibi-
tion of HIF activity observed with LBH589. Moreover,
HDAC inhibition at early time points has also been
demonstrated to disrupt the p300:HIF complex, a criti-
cal component of HIF transactivation, resulting in
decreased HIF transcriptional activity [88]. Adding to
this complexity, HIF directly interacts with, and is regu-
lated by, HDACs [90] illustrating several nodal points by
which Hsp90 and HDAC inhibitors may distinctly
impact upon HIF function.
To more comprehensively evaluate the relative efficacy
of these agents against specific metrics, we examined
key anticancer properties beyond HIF transcription.
Sub-nanomolar concentrations of 17-AAG and EC154
profoundly suppressed CCRCC cell motility, whereas
higher concentrations were required to diminish
CCRCC-mediated HUVEC tubule formation. Although
LBH589 demonstrated the most potent suppression of
both VEGF transcription and secreted protein, it only
modestly prevented tubule formation in 786-O. Our
tubule formation results support the notion that Hsp90
inhibiting agents, in part via their suppressive effects
upon HIF, may be utilized clinically to reduce the vascu-
larity associated with CCRCC and other solid tumors
[31,67]. Although LBH589 did not restore barrier func-
tion, another report demonstrates that this agent, in
combination with rapamycin in a preclinical model, was
effective in reducing CCRCC angiogenesis [15]. A recent
report found that pre-incubation with the HDAC6 inhi-
bitor tubacin prevents thrombin induced barrier damage
[91], suggesting that the effects of HDAC inhibition
upon vessel permeability could vary greatly depending
upon a variety of factors. Therefore, the ECIS assay may
be a useful approach to more fully interrogate the ability
of LBH589, and other HDACIs, to restore endothelial
cell function alone and in combination with currently
utilized anticancer agents. The ability of these agents to
preserve endothelial cell integrity could have significant
effects on clinical outcome and warrants further atten-
tion. Clinically, vascular permeability can promote
tumor cell TEM and metastasis [82] and poses a further
challenge in diminishing the delivery and efficacy of
chemo- and radio-therapies [92]. Our results suggest
that these agents may have utility in ‘normalizing’ the
tumor vasculature, an effect that improves chemo- and
radio-therapy [92]. Although not formally demonstrated
for Hsp90 inhibitors, 17-AAG and radicicol have been
shown to improve endothelial barrier formation and res-
cue barrier in the presence of damaging agents including
thrombin, VEGF, and phorbal ester [84,85]. In addition,
we previously demonstrated that both GA and 17-AAG
potentiate the radiation response of cervical tumor cells
in vitro and in vivo [29]. Our data suggest that EC154
exhibits a similar capacity as 17-AAG in terms of its
ability to restore barrier function, and may therefore
represent a viable clinical candidate.
Conclusions
In sum, our transcriptional results indicate that Hsp90
inhibition may affect HIF-dependent gene transcription
through at least two mechanisms; by direct inhibition
of transcriptional activity at early time points, and by
promotion of HIF-1a degradation at later time points.
This further highlights the complexity of Hsp90 inhibi-
tor effects and weakens the notion that variations of
HIF-a isoform stability is a primary reason for the
clinical failure of these agents [34]. Importantly, our
results also highlight that HIF expression is not neces-
sarily a reliable surrogate for interrogating the HIF tar-
geting efficacy of Hsp90 inhibitors. This is a
particularly salient finding in light of recent efforts to
improve in vivo and intratumoral imaging of Hsp90
client proteins as a surrogate for monitoring inhibitor
activity [93-97]. Moreover, our results further indicate
that levels of HIF regulated cytokines such as VEGF
may also be unreliable surrogates for HIF activity,
demonstrated by the observed differential effects of
Hsp90 inhibition upon intracellular and secreted
VEGF. This finding further highlights the challenge in
choosing appropriate biomarkers, in that the histo-
chemical analysis of tumor tissues for VEGF expression
would indicate less robust drug dependent effects com-
pared with an analysis of secreted levels of the same
protein. Our findings highlight the need to integrate
multiple, diverse, and functional endpoints to more
appropriately discern the effects of Hsp90 inhibition
upon HIF function. With more than a dozen new
Hsp90 inhibitors currently under clinical evaluation
[98], there is a critical need to establish relevant and
reliable surrogates and biomarkers for evidence of
Hsp90 inhibition. The identification of these readouts
and their subsequent incorporation into clinical trials
will provide useful indicators of positive response. Our
findings offer useful metrics and considerations to
guide the preclinical and clinical evaluation of conven-
tional and novel Hsp90 inhibitors.
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Additional file 1: Figure S1. Dose dependent effects of 17-AAG, EC154,
and LBH589 upon HIF-dependent gene transcription in 786-O. 786-O
cells were treated for 16 h with the indicated concentrations of
inhibitors, total mRNA was isolated and HIF-a regulated genes analyzed
by QRT-PCR. Values were normalized to GAPDH and are presented
relative to control, with standard deviation. Stably transfected VHL
replaced cells were used as a control condition for HIF suppression.
Additional file 2: Figure S2. Effects of 17-AAG, EC154, and LBH589
upon intracellular VEGF expression in CCRCC cells. CCRCC cells (786-O
and UMRC2) were pre-treated for 4 h (1 μM 17-AAG, 100 nM EC154, 100
nM LBH589) in reduced serum DMEM (3% FBS). Cells were then re-
incubated for an additional 16 h with freshly prepared treatments in
reduced serum medium. Whole cell lysate was collected and VEGF levels
were determined by ELISA. Values are normalized to total cellular protein
and presented as a percent of DMSO treated control with standard
deviation. All drug treatments significantly reduced HIF-dependent
reporter gene expression (*) in both cell types with the exception of
EC154 in 786-O, as determined by ANOVA and Student’s t-test (p < 0.05).
Additional file 3: Figure S3. Administration of 17-AAG, EC154, and
LBH589 does not affect CCRCC viability within 16 h. CCRCC cells were
incubated for 16 h with vehicle or the indicated agents and cell viability
was determined by MTT assay, with data presented as a percent of
control cells, with standard deviation.
Additional file 4: Figure S4. Suppression of VEGF and uPa secretion by
EC154 and LBH589 in CCRCC cells under hypoxia. CCRCC cells were pre-
treated for 4 h with inhibitors in reduced serum DMEM (3% FBS), and
incubated for an additional 16 h with freshly prepared treatments in
reduced serum medium at 1% O2. Conditioned medium was collected
and VEGF and uPa levels were analyzed by ELISA. Values were
normalized to total protein in conditioned medium and presented
relative to controls, with standard deviation.
Additional file 5: Figure S5. VEGF elicits a modest breach of endothelial
integrity, which is rescued by 17-AAG. Monolayers of HUVEC cells were
allowed to reach a minimal TEER plateau and then incubated with VEGF
(50 ng/mL) in the presence or absence of 17-AAG (1 μM). Impedance
was measured at 5 min intervals, normalized to levels just prior to the
addition of effectors, and presented relative to untreated control. The
traces shown represent an average of two replicates per condition.
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